Claims for Patent: 10,456,470

Summary for Patent: 10,456,470

Title:	Diagnostic methods and compositions for treatment of glioblastoma
Abstract:	The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
Inventor(s):	Bais; Carlos (South San Francisco, CA), Bourgon; Richard (South San Francisco, CA), Phillips; Heidi (South San Francisco, CA), Sandmann; Thomas (South San Francisco, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	14/471,734
Patent Claims:	1. A method of treating a patient having a proneural subtype glioblastoma who is likely to respond to treatment with an anti-VEGF antibody, the method comprising: (a) detecting expression of at least one of the genes set forth in Table 1, 2, or 3 in a biological sample obtained from the patient prior to administration of the anti-VEGF antibody to the patient; (b) comparing the expression level of the at least one gene to a reference expression level of the at least one gene, wherein a change in the level of expression of the at least one gene in the patient sample relative to the reference expression level identifies the patient as one who has a glioblastoma of the proneural subtype and is likely to respond to treatment with the anti-VEGF antibody; and (c) administering an effective amount of the anti-VEGF antibody to the patient identified as likely to respond to treatment with the anti-VEGF antibody. 2. The method of claim 1, wherein the reference expression level is the median level of expression of the at least one gene in a population of patients having glioblastomas. 3. The method of claim 1, wherein the reference expression level is the median level of expression of the at least one gene in patients having glioblastomas and identified as not responding to anti-VEGF antibody treatment. 4. The method of claim 1, wherein the change in level of expression of the at least one gene in the patient sample is an increase relative to the reference level. 5. The method of claim 1, wherein the change in level of expression of the at least one gene in the patient sample is a decrease relative to the reference level. 6. The method of claim 1, further comprising detecting expression of at least two of said genes in the biological sample from the patient. 7. The method of claim 1, wherein the administered anti-VEGF antibody is bevacizumab. 8. The method of claim 1, wherein the administered anti-VEGF antibody comprises a variable heavy chain (VH) and a variable light chain (VL), wherein said VH has an amino acid sequence of SEQ ID NO: 2 and said VL has an amino acid sequence of SEQ ID NO: 1. 9. The method of claim 1, further comprising administering an effective amount of at least a second agent. 10. The method of claim 9, wherein the second agent is selected from the group consisting of: an anti-neoplastic agent, a chemotherapeutic agent, a growth inhibitory agent, and a cytotoxic agent, or combinations thereof. 11. The method of claim 1, wherein responsiveness to treatment with the anti-VEGF antibody is an increase in overall survival. 12. The method of claim 1, wherein the at least one gene is selected from the group consisting of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2. 13. The method of claim 12, wherein the change in level of expression of the at least one gene in the patient sample is an increase relative to the reference level. 14. A method of treating a patient having a proneural subtype glioblastoma who is likely to respond to treatment with an anti-VEGF antibody, the method comprising: (a) detecting expression of at least one gene in a biological sample obtained from the patient prior to administration of the anti-VEGF antibody to the patient, wherein the at least one gene is selected from the group consisting of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and PFN2; (b) comparing the expression level of the at least one gene to a reference expression level of the at least one gene, wherein an increase in the level of expression of NCAM1, OMG, PRKCZ, GALNT13, GPR17, DNM3, FERMT1, SNAP91, ABHD6, and/or PFN2 in the patient sample relative to the reference expression level identifies the patient as one who has a glioblastoma of the proneural subtype and is likely to respond to treatment with the anti-VEGF antibody; and (c) administering an effective amount of the anti-VEGF antibody to the patient identified as likely to respond to treatment with the anti-VEGF antibody.

Details for Patent 10,456,470

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-11-24